

NEWS RELEASE

iX Biopharma inks agreement with Cannatrek to supply Xativa™, the world's first freeze-dried sublingual medicinal cannabis wafer, to the Australian market

- ✓ Xativa™, which contains a nano-emulsion of broad-spectrum CBD (cannabidiol) delivered using the Group's patented WaferiX sublingual delivery technology, is a highly differentiated and superior dosage form that improves bioavailability of CBD, providing patients with rapid absorption, faster therapeutic action and predictable outcome
- ✓ Cannatrek, a fully licensed medicinal cannabis enterprise with an extensive global wholesale and national distribution network in Australia will distribute Xativa™ to pharmacies across Australia
- ✓ The supply to Cannatrek marks the Group's official entry into the high-growth Australian cannabis market which is expected to grow from US\$0.04 billion in 2020 to US\$1.23 billion by 2024

Singapore, 29 April 2020 – Specialty pharmaceutical company **iX Biopharma Ltd** (SGX:42C) ("iX Biopharma" or, together with its subsidiaries, "the Group") is pleased to announce that its wholly-owned subsidiary, iX Syrinx ("Syrinx"), has formalised a supply agreement with Cannatrek Medical Pty Ltd ("Cannatrek"), a wholly-owned subsidiary of Cannatrek Ltd. Cannatrek is a medicinal cannabis enterprise with a national distribution network in Australia and participates heavily in doctor and patient education programmes for medicinal cannabis.

The existing delivery forms available in the market today suffer from the lack of fixed unit dosages, inconsistent absorption and variable or poor bioavailability. Leveraging on iX Biopharma's novel and patented WaferiX™ sublingual delivery technology, the Group has developed Xativa™ to address this gap in the market.

Together with Cannatrek, the Group will commence supply and distribution activities of Xativa™, the Group's proprietary medicinal CBD (cannabidiol) sublingual wafer, to pharmacies across Australia. Xativa™ will be prescribed by medical practitioners to patients via the Special Access Scheme and Authorised Prescriber pathway administered by the Therapeutic Goods Administration ("TGA") of Australia.

Tommy Huppert, CEO of Cannatrek said: *"Driven by our commitment to provide patients with safe, affordable and effective treatments, our partnership with iX Biopharma has been a natural progression in our growth journey. Built upon the novel and patented WaferiX technology, Xativa, through its unique and superior sublingual dosage form, is well-positioned to disrupt the current market of medicinal cannabis products."*

Ms Eva Tan, Director of Corporate and Commercial Strategy of iX Biopharma said: *"We are excited to partner with leaders like Cannatrek to reach Australian patients through their well-established network of prescribers and pharmacies. Patients are now more knowledgeable about the advantages of sublingually administered cannabis medicines in increasing bioavailability and improving patient outcomes. We are confident that our sublingual technology, which is clinically proven and widely used across our pharmaceutical and nutraceutical product portfolio, will allow us to better serve patient need and expectation."*

Today, the legalisation and widespread use of cannabis and cannabinoids around the world is happening at an unprecedented pace. CBD in particular, one of the primary non-intoxicating compounds found in the cannabis plant, has attracted growing interest due to its safety and efficacy in treating many health conditions, including chronic pain, anxiety, movement and sleep disorders. In view of these prevailing trends, the Australian cannabis market is expected to grow exponentially from an estimated US\$0.04 billion in 2020 to US\$1.23 billion by 2024¹.

For more information on Xativa™, please refer to the link below:

[\[http://www.ixbiopharma.com/xativa\]](http://www.ixbiopharma.com/xativa)

- The End -

About iX Biopharma Ltd

iX Biopharma is a specialty pharmaceutical and nutraceutical company listed on the Catalist board of the Stock Exchange of Singapore (SGX-ST), operating a fully integrated business model from drug development to manufacturing and supply, with facilities in Australia. The Group is focused on the development and commercialisation of therapies for diseases of the central nervous system using novel, patent-protected formulations for sublingual delivery.

iX Biopharma's pipeline of products under development includes Wafermine (ketamine wafer) and BnoX (buprenorphine wafer) for pain management. iX Biopharma's drugs for the treatment of erectile dysfunction, Wafesil, a sublingual sildenafil wafer, and Silcap, have been registered in Australia. iX Biopharma has developed Xativa, the world's first freeze-dried sublingual medicinal cannabis wafer.

The Group's nutraceuticals division, Entity Health Limited, is engaged in the development and commercialisation of nutraceutical products that address specific conditions and improve quality of life. It distributes its Entity line of nutraceutical products through more than 200 pharmacies and health food shops in Australia and online.

About Cannatrek Ltd

Cannatrek is a fully licensed medicinal cannabis enterprise in Australia, operating as a first-mover in the nascent medical cannabis industry, with licences in hand to operate from seed to patient. Cannatrek is developing complete vertical integration, from biomedical research and education, cultivation and green technology, through to processing and smart packaging, as well as a secure blockchain to cover end-to-end distribution. More recently, Cannatrek was awarded Major Project Status from the Federal Government for its \$160.0 million production facility in the Victorian regional city of Shepparton. When operating at full production, Cannatrek aims to produce 160 tonnes of medicinal cannabis per year, which will make it one of the world's largest medicinal cannabis facilities. Cannatrek also has an extensive global wholesale and national distribution network in Australia.

For more information, visit <http://cannatrek.com.au/>

¹ Prohibition Partners, 2020, "The Oceania Cannabis Report, Second Edition, April 2020"

Contact for media:

Dr Janakan Krishnarajah

Chief Operating Officer and Chief Medical Officer

T: +65 6235 2270

E: j.krishnarajah@ixbiopharma.com

Eva Tan

Director, Corporate and Commercial Strategy

T: +65 6235 3212

E: eva.tan@ixbiopharma.com

Investor Relations:

Kamal Samuel/James Bywater/Jonathan Wee

T: +65 6438 2990

E: Tech@financialpr.com.sg

This announcement has been reviewed by the Company's sponsor, CIMB Bank Berhad, Singapore Branch ("Sponsor") in accordance with Rule 226(2)(b) of the Catalist Rules. This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr. Yee Chia Hsing, Head, Catalist. The contact particulars are 50 Raffles Place, #09-01 Singapore Land Tower, Singapore 048623, telephone: (65) 6337-5115.